Clinical Trials

How Can Biopharma Optimize Patient Recruitment in Clinical Trials?
Research & Development How Can Biopharma Optimize Patient Recruitment in Clinical Trials?

Patient recruitment for clinical trials in the biopharma industry is often a challenging task. Successful recruitment strategies can significantly impact the efficiency and effectiveness of clinical trials, ultimately contributing to bringing new therapies to market faster. To achieve this,

Zephyrm Targets IPO to Fund Advanced Trials for Cell Therapy ZH901
Research & Development Zephyrm Targets IPO to Fund Advanced Trials for Cell Therapy ZH901

Zephyrm Bioscience has announced its intention to pursue an initial public offering (IPO) on the Hong Kong stock exchange. The biotech company aims to secure significant funding to advance its lead cell therapy candidate, ZH901, into phase 3 clinical trials. ZH901 is targeted at treating both a

Excellos and Galapagos Partner to Advance CAR-T Therapy Manufacturing
Research & Development Excellos and Galapagos Partner to Advance CAR-T Therapy Manufacturing

The world of medical and pharmaceutical advancements is frequently marked by innovative partnerships that push the boundaries of what is possible in patient care. One such collaboration has recently emerged between Excellos Inc. and Galapagos. These two entities have teamed up to enhance the

Which Top Biopharma Conferences Should You Attend in 2025?
Research & Development Which Top Biopharma Conferences Should You Attend in 2025?

The biotech and pharmaceutical industries are highly dynamic fields reliant on constant innovation, robust networking, and strategic investor relations. Professionals in these sectors must attend top biopharma conferences to keep pace with the latest advancements, regulatory trends, and emerging

Seelos, U.S. Army Partner on SLS-002 for Breakthrough PTSD Treatment
Research & Development Seelos, U.S. Army Partner on SLS-002 for Breakthrough PTSD Treatment

Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, has reached a significant milestone in the development of treatments for post-traumatic stress disorder (PTSD). The company recently announced a Material Transfer Agreement (MTA) with the U.S. Army Medical

BioAge's $198M IPO Marks Major Shift Towards Innovative Obesity Drugs
Research & Development BioAge's $198M IPO Marks Major Shift Towards Innovative Obesity Drugs

BioAge Labs has recently garnered significant attention with its successful initial public offering (IPO), raising a formidable $198 million. Demonstrating the company's strategic pivot towards obesity drug research, this financial feat is particularly notable given the challenging environment

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later